Sergio A Jimenez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/102026/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Progressive multifocal fibrosing neuropathy: description of a novel disease. Acta Neuropathologica Communications, 2022, 10, 34.	2.4	0
2	Tyrosine kinases in the pathogenesis of tissue fibrosis in systemic sclerosis and potential therapeutic role of their inhibition. Translational Research, 2021, 231, 139-158.	2.2	20
3	Global gene expression analysis of systemic sclerosis myofibroblasts demonstrates a marked increase in the expression of multiple NBPF genes. Scientific Reports, 2021, 11, 20435.	1.6	1
4	Oxidative Stress Induced by Reactive Oxygen Species (ROS) and NADPH Oxidase 4 (NOX4) in the Pathogenesis of the Fibrotic Process in Systemic Sclerosis: A Promising Therapeutic Target. Journal of Clinical Medicine, 2021, 10, 4791.	1.0	22
5	Serine-Threonine Kinase inhibition as antifibrotic therapy: TGF-β and ROCK inhibitors. Rheumatology, 2021, , .	0.9	1
6	Increased expression of interferon regulated and antiviral response genes in CD31+/CD102+ lung microvascular endothelial cells from systemic sclerosis patients with end-stage interstitial lung disease. Clinical and Experimental Rheumatology, 2021, 39, 1298-1306.	0.4	5
7	Recurrence of progressive skin involvement following discontinuation or dose reduction of Mycophenolate Mofetil treatment in patients with diffuse Systemic Sclerosis. Seminars in Arthritis and Rheumatism, 2020, 50, 135-139.	1.6	12
8	Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study. Rheumatology, 2020, 59, 1684-1694.	0.9	27
9	Molecular characteristics and functional differences of anti-PM/Scl autoantibodies and two other distinct and unique supramolecular structures known as "EXOSOMES― Autoimmunity Reviews, 2020, 19, 102644.	2.5	2
10	Chemical exposure-induced systemic fibrosing disorders: Novel insights into systemic sclerosis etiology and pathogenesis. Seminars in Arthritis and Rheumatism, 2020, 50, 1226-1237.	1.6	5
11	Long non-coding RNA HOTAIR drives EZH2-dependent myofibroblast activation in systemic sclerosis through miRNA 34a-dependent activation of NOTCH. Annals of the Rheumatic Diseases, 2020, 79, 507-517.	0.5	60
12	Increased expression of the transforming growth factor β–inducible gene HIC-5 in systemic sclerosis skin and fibroblasts: a novel antifibrotic therapeutic target. Rheumatology, 2020, 59, 3092-3098.	0.9	5
13	Role of microRNA in the pathogenesis of systemic sclerosis tissue fibrosis and vasculopathy. Autoimmunity Reviews, 2019, 18, 102396.	2.5	50
14	Endothelial to Mesenchymal Transition: Role in Physiology and in the Pathogenesis of Human Diseases. Physiological Reviews, 2019, 99, 1281-1324.	13.1	325
15	Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis. Arthritis and Rheumatology, 2019, 71, 1553-1570.	2.9	75
16	Abrogation of transforming growth factor-Î ² -induced tissue fibrosis in mice with a global genetic deletion of Nox4. Laboratory Investigation, 2019, 99, 470-482.	1.7	19
17	El contenido digital en las administraciones locales: condiciones ontológicas y organizativas para su creación y gestión. En Contexto, 2019, 8, 93-114.	0.1	0
18	Identification of novel systemic sclerosis biomarkers employing aptamer proteomic analysis. Rheumatology, 2018, 57, 1698-1706.	0.9	9

#	Article	IF	CITATIONS
19	Abrogation of transforming growth factor-β-induced tissue fibrosis in TBRIcaCol1a2Cre transgenic mice by the second generation tyrosine kinase inhibitor SKI-606 (Bosutinib). PLoS ONE, 2018, 13, e0196559.	1.1	14
20	Existing and novel biomarkers for precision medicine in systemic sclerosis. Nature Reviews Rheumatology, 2018, 14, 421-432.	3.5	48
21	Simultaneous inhibition of c-Abl and Src kinases abrogates the exaggerated expression of profibrotic genes in cultured systemic sclerosis dermal fibroblasts. Clinical and Experimental Rheumatology, 2018, 36 Suppl 113, 36-44.	0.4	3
22	Multiplex assessment of serum cytokine and chemokine levels in idiopathic morphea and vitamin K1-induced morphea. Clinical Rheumatology, 2017, 36, 1173-1178.	1.0	8
23	Endothelial cell-specific activation of transforming growth factor-Î ² signaling in mice induces cutaneous, visceral, and microvascular fibrosis. Laboratory Investigation, 2017, 97, 806-818.	1.7	20
24	PTP4A1 promotes TGFβ signaling and fibrosis in systemic sclerosis. Nature Communications, 2017, 8, 1060.	5.8	46
25	Human Fibrotic Diseases: Current Challenges in Fibrosis Research. Methods in Molecular Biology, 2017, 1627, 1-23.	0.4	108
26	Biomarkers in Systemic Sclerosis. , 2017, , 245-260.		0
27	Exosomes isolated from serum of systemic sclerosis patients display alterations in their content of profibrotic and antifibrotic microRNA and induce a profibrotic phenotype in cultured normal dermal fibroblasts. Clinical and Experimental Rheumatology, 2017, 35 Suppl 106, 21-30.	0.4	25
28	A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study. Annals of the Rheumatic Diseases, 2016, 75, 163-169.	0.5	82
29	Endothelial to Mesenchymal Transition (EndoMT) in the Pathogenesis of Human Fibrotic Diseases. Journal of Clinical Medicine, 2016, 5, 45.	1.0	215
30	Endothelial Cells Expressing Endothelial and Mesenchymal Cell Gene Products in Lung Tissue From Patients With Systemic Sclerosis–Associated Interstitial Lung Disease. Arthritis and Rheumatology, 2016, 68, 210-217.	2.9	91
31	Role of muscarinic-3 receptor antibody in systemic sclerosis: correlation with disease duration and effects of IVIG. American Journal of Physiology - Renal Physiology, 2016, 310, G1052-G1060.	1.6	49
32	Age-related effects of increasing postural challenge on eye movement onset latencies to visual targets. Experimental Brain Research, 2016, 234, 1599-1609.	0.7	3
33	Endothelial to mesenchymal transition (EndoMT) in the pathogenesis of Systemic Sclerosis-associated pulmonary fibrosis and pulmonary arterial hypertension. Myth or reality?. Matrix Biology, 2016, 51, 26-36.	1.5	79
34	Treatment of rapidly progressive systemic sclerosis: current and futures perspectives. Expert Opinion on Orphan Drugs, 2016, 4, 31-47.	0.5	20
35	Stimulation of Transforming Growth Factor-β1-Induced Endothelial-To-Mesenchymal Transition and Tissue Fibrosis by Endothelin-1 (ET-1): A Novel Profibrotic Effect of ET-1. PLoS ONE, 2016, 11, e0161988.	1.1	76
36	Increased Expression of NAPDH Oxidase 4 in Systemic Sclerosis Dermal Fibroblasts: Regulation by Transforming Growth Factor Î ² . Arthritis and Rheumatology, 2015, 67, 2749-2758.	2.9	40

Sergio A Jimenez

4

#	Article	IF	CITATIONS
37	Role of Cellular Senescence and NOX4-Mediated Oxidative Stress in Systemic Sclerosis Pathogenesis. Current Rheumatology Reports, 2015, 17, 473.	2.1	37
38	Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1106-15.	3.3	376
39	The significance of macrophage polarization subtypes for animal models of tissue fibrosis and human fibrotic diseases. Clinical and Translational Medicine, 2015, 4, 2.	1.7	130
40	Altered MCM Protein Levels and Autophagic Flux in Aged and Systemic Sclerosis Dermal Fibroblasts. Journal of Investigative Dermatology, 2014, 134, 2321-2330.	0.3	51
41	2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis and Rheumatism, 2013, 65, 2737-2747.	6.7	2,359
42	Acute retinal artery occlusion in systemic sclerosis: A rare manifestation of systemic sclerosis fibroproliferative vasculopathy. Seminars in Arthritis and Rheumatism, 2013, 43, 204-208.	1.6	11
43	2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Annals of the Rheumatic Diseases, 2013, 72, 1747-1755.	0.5	1,705
44	Strategies for anti-fibrotic therapies. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 1088-1103.	1.8	146
45	Caveolin-1 Deficiency Induces Spontaneous Endothelial-to-Mesenchymal Transition in Murine Pulmonary Endothelial Cells inAVitro. American Journal of Pathology, 2013, 182, 325-331.	1.9	53
46	Potential role of human-specific genes, human-specific microRNAs and human-specific non-coding regulatory RNAs in the pathogenesis of Systemic Sclerosis and Sjögren's Syndrome. Autoimmunity Reviews, 2013, 12, 1046-1051.	2.5	59
47	Role of Oxidative Stress and Reactive Oxygen Radicals in the Pathogenesis of Systemic Sclerosis. , 2013, , 183-197.		1
48	Collagen Content in Skin and Internal Organs of the Tight Skin Mouse: An Animal Model of Scleroderma. Biochemistry Research International, 2013, 2013, 1-8.	1.5	14
49	Role of Endothelial to Mesenchymal Transition in the Pathogenesis of the Vascular Alterations in Systemic Sclerosis. ISRN Rheumatology, 2013, 2013, 1-15.	1.9	92
50	Induction of a type I interferon signature in normal human monocytes by gadolinium-based contrast agents: comparison of linear and macrocyclic agents. Clinical and Experimental Immunology, 2013, 175, 113-125.	1.1	25
51	Chitinase 1 Is a Biomarker for and Therapeutic Target in Scleroderma-Associated Interstitial Lung Disease That Augments TGF-β1 Signaling. Journal of Immunology, 2012, 189, 2635-2644.	0.4	90
52	Gadolinium Compounds Signaling through TLR 4 and TLR 7 in Normal Human Macrophages: Establishment of a Proinflammatory Phenotype and Implications for the Pathogenesis of Nephrogenic Systemic Fibrosis. Journal of Immunology, 2012, 189, 318-327.	0.4	51
53	A Prospective Observational Study of Mycophenolate Mofetil Treatment in Progressive Diffuse Cutaneous Systemic Sclerosis of Recent Onset. Journal of Rheumatology, 2012, 39, 1241-1247.	1.0	76

54 Nephrogenic Systemic Fibrosis. , 2012, , 137-159.

#	Article	IF	CITATIONS
55	Effects of Scleroderma Antibodies and Pooled Human Immunoglobulin on Anal Sphincter and Colonic Smooth Muscle Function. Gastroenterology, 2012, 143, 1308-1318.	0.6	38
56	Predictors of early mortality in systemic sclerosis: a case–control study comparing early versus late mortality in systemic sclerosis. Rheumatology International, 2012, 32, 3841-3844.	1.5	7
57	Systemic sclerosis disease modification clinical trials design: Quo vadis?. Arthritis Care and Research, 2012, 64, n/a-n/a.	1.5	7
58	Effect of oxidative stress on protein tyrosine phosphatase 1B in scleroderma dermal fibroblasts. Arthritis and Rheumatism, 2012, 64, 1978-1989.	6.7	38
59	Molecular mechanisms of endothelial to mesenchymal cell transition (EndoMT) in experimentally induced fibrotic diseases. Fibrogenesis and Tissue Repair, 2012, 5, S7.	3.4	79
60	Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise. Arthritis Care and Research, 2012, 64, 351-357.	1.5	49
61	Role of Endothelial-Mesenchymal Transition (EndoMT) in the Pathogenesis of Fibrotic Disorders. American Journal of Pathology, 2011, 179, 1074-1080.	1.9	480
62	46,XX SRY-Positive Male Syndrome Presenting with Primary Hypogonadism in the Setting of Scleroderma. Endocrine Practice, 2011, 17, 95-98.	1.1	13
63	Scleroderma Renal Crisis-Like Acute Renal Failure Associated With Mucopolysaccharide Accumulation in Renal Vessels in a Patient With Scleromyxedema. Journal of Clinical Rheumatology, 2011, 17, 318-322.	0.5	12
64	Protein kinase Cl̂´ and câ€Abl kinase are required for transforming growth factor l̂² induction of endothelial–mesenchymal transition in vitro. Arthritis and Rheumatism, 2011, 63, 2473-2483.	6.7	90
65	Tyrosine kinase inhibitor therapy for systemic sclerosis: Quo Vadis?. Arthritis and Rheumatism, 2011, 63, 3199-3203.	6.7	7
66	Effect of Protein Kinase C delta (PKC-Î) Inhibition on the Transcriptome of Normal and Systemic Sclerosis Human Dermal Fibroblasts In Vitro. PLoS ONE, 2011, 6, e27110.	1.1	24
67	Role of Growth Factors in the Pathogenesis of Tissue Fibrosis in Systemic Sclerosis. Current Rheumatology Reviews, 2010, 6, 283-294.	0.4	25
68	Maternal Mixed Connective Tissue Disease and Offspring with Chondrodysplasia Punctata. Seminars in Arthritis and Rheumatism, 2010, 39, 410-416.	1.6	18
69	NFκB activation and stimulation of chemokine production in normal human macrophages by the gadolinium-based magnetic resonance contrast agent Omniscan: possible role in the pathogenesis of nephrogenic systemic fibrosis. Annals of the Rheumatic Diseases, 2010, 69, 2024-2033.	0.5	39
70	Persistent activation of dermal fibroblasts from patients with gadolinium-associated nephrogenic systemic fibrosis. Annals of the Rheumatic Diseases, 2010, 69, 2017-2023.	0.5	37
71	Assessment of tissue fibrosis in skin biopsies from patients with systemic sclerosis employing confocal laser scanning microscopy: an objective outcome measure for clinical trials?. Rheumatology, 2010, 49, 1069-1075.	0.9	15
72	Biomarkers in systemic sclerosis. Biomarkers in Medicine, 2010, 4, 133-147.	0.6	72

#	Article	IF	CITATIONS
73	Proteomic Analysis Identification of a Pattern of Shared Alterations in the Secretome of Dermal Fibroblasts from Systemic Sclerosis and Nephrogenic Systemic Fibrosis. American Journal of Pathology, 2010, 177, 1638-1646.	1.9	23
74	Narrative Review: Fibrotic Diseases: Cellular and Molecular Mechanisms and Novel Therapies. Annals of Internal Medicine, 2010, 152, 159.	2.0	185
75	Improvement of Severe Systemic Sclerosis-associated Gastric Antral Vascular Ectasia Following Immunosuppressive Treatment with Intravenous Cyclophosphamide. Journal of Rheumatology, 2009, 36, 1653-1656.	1.0	37
76	The proadhesive phenotype of systemic sclerosis skin promotes myeloid cell adhesion via ICAM-1 and VCAM-1. Rheumatology, 2009, 48, 734-740.	0.9	29
77	Immunoglobulins from scleroderma patients inhibit the muscarinic receptor activation in internal anal sphincter smooth muscle cells. American Journal of Physiology - Renal Physiology, 2009, 297, G1206-G1213.	1.6	63
78	Primary Osteoarthritis No Longer Primary: Three Subsets with Distinct Etiological, Clinical, and Therapeutic Characteristics. Seminars in Arthritis and Rheumatism, 2009, 39, 71-80.	1.6	130
79	Mechanism of NSF: New evidence challenging the prevailing theory. Journal of Magnetic Resonance Imaging, 2009, 30, 1277-1283.	1.9	44
80	Induction of the expression of profibrotic cytokines and growth factors in normal human peripheral blood monocytes by gadolinium contrast agents. Arthritis and Rheumatism, 2009, 60, 1508-1518.	6.7	78
81	Caveolin-1â^'/â^' Null Mammary Stromal Fibroblasts Share Characteristics with Human Breast Cancer-Associated Fibroblasts. American Journal of Pathology, 2009, 174, 746-761.	1.9	123
82	Molecular ablation of transforming growth factor β signaling pathways by tyrosine kinase inhibition: The coming of a promising new era in the treatment of tissue fibrosis. Arthritis and Rheumatism, 2008, 58, 2219-2224.	6.7	28
83	Decreased expression of caveolin 1 in patients with systemic sclerosis: Crucial role in the pathogenesis of tissue fibrosis. Arthritis and Rheumatism, 2008, 58, 2854-2865.	6.7	159
84	Targeting NF-κB: A Promising Molecular Therapy in Inflammatory Arthritis. International Reviews of Immunology, 2008, 27, 351-374.	1.5	47
85	Caveolin-1, transforming growth factor-Î ² receptor internalization, and the pathogenesis of systemic sclerosis. Current Opinion in Rheumatology, 2008, 20, 713-719.	2.0	118
86	Human Collagen Krox Up-regulates Type I Collagen Expression in Normal and Scleroderma Fibroblasts through Interaction with Sp1 and Sp3 Transcription Factors. Journal of Biological Chemistry, 2007, 282, 32000-32014.	1.6	46
87	Nephrogenic Systemic Fibrosis/Nephrogenic Fibrosing Dermopathy: Clinical Aspects. Skinmed, 2007, 6, 24-27.	0.0	7
88	Significance of Ground-glass Opacity on HRCT in Long-term Follow-up of Patients With Systemic Sclerosis. Journal of Thoracic Imaging, 2007, 22, 120-124.	0.8	61
89	T cells expressing allograft inflammatory factor 1 display increased chemotaxis and induce a profibrotic phenotype in normal fibroblasts in vitro. Arthritis and Rheumatism, 2007, 56, 3478-3488.	6.7	44
90	Regulation of the human SOX9 promoter by Sp1 and CREB. Experimental Cell Research, 2007, 313, 1069-1079.	1.2	79

#	Article	IF	CITATIONS
91	Acute myocardial infarction in systemic sclerosis patients: a case series. Clinical Rheumatology, 2007, 26, 965-968.	1.0	30
92	The role of allograft inflammatory factor 1 in systemic sclerosis. Current Opinion in Rheumatology, 2006, 18, 588-593.	2.0	11
93	Morbidity and mortality of patients diagnosed with systemic sclerosis after the age of 75: a nested case-control study. Clinical Rheumatology, 2006, 25, 831-834.	1.0	32
94	Statins and the vasculopathy of systemic sclerosis: Potential therapeutic agents?. Autoimmunity Reviews, 2006, 5, 25-32.	2.5	35
95	Description of 12 Cases of Nephrogenic Fibrosing Dermopathy and Review of the Literature. Seminars in Arthritis and Rheumatism, 2006, 35, 238-249.	1.6	241
96	Inhibition of systemic sclerosis dermal fibroblast type I collagen production and gene expression by simvastatin. Arthritis and Rheumatism, 2006, 54, 1298-1308.	6.7	45
97	Expression of allograft inflammatory factor 1 in tissues from patients with systemic sclerosis and in vitro differential expression of its isoforms in response to transforming growth factor β. Arthritis and Rheumatism, 2006, 54, 2616-2625.	6.7	64
98	Systemic Sclerosis. , 2006, , 979-989.		0
99	Microchimerism and systemic sclerosis. Current Opinion in Rheumatology, 2005, 17, 86-90.	2.0	41
100	Scleroderma Fibroblast Survival in Aktion. Journal of Investigative Dermatology, 2005, 124, viii-xi.	0.3	4
101	Case 35-2004: Nephrogenic Fibrosing Dermopathy. New England Journal of Medicine, 2005, 352, 1723-1724.	13.9	13
102	Demonstration of Autoimmunity in the Tight Skin-2 Mouse: A Model for Scleroderma. Journal of Immunology, 2005, 175, 2418-2426.	0.4	50
103	Regulation of the human Sox9 promoter by the CCAAT-binding factor. Matrix Biology, 2005, 24, 185-197.	1.5	35
104	Single amino acid substitutions in the C-terminus of collagen II alter its affinity for collagen IX. Biochemical and Biophysical Research Communications, 2005, 335, 749-755.	1.0	5
105	Increased incidence of carcinoma of the tongue in patients with systemic sclerosis. Journal of Rheumatology, 2005, 32, 637-41.	1.0	45
106	Following the Molecular Pathways toward an Understanding of the Pathogenesis of Systemic Sclerosis. Annals of Internal Medicine, 2004, 140, 37.	2.0	158
107	A Role for the Androgen Receptor in Collagen Content of the Skin. Journal of Investigative Dermatology, 2004, 123, 1052-1056.	0.3	56
108	Hypoxia inducible factor-1 alpha expression in human normal and osteoarthritic chondrocytes11Supported by NIH/NIAMS Program Project grant (AR-39740) to S.A.J. I. C. was supported by a fellowship from Fundacao de Amparoâ€ĩa Ciencia do Estado de Sao Paulo Osteoarthritis and Cartilage, 2004, 12, 336-345.	0.6	121

#	Article	IF	CITATIONS
109	Primary B-cell lymphoma of the tongue in a patient with systemic sclerosis. Oral Oncology, 2004, 40, 103-106.	0.8	14
110	Impaired Rectoanal Inhibitory Response in Scleroderma (Systemic Sclerosis): An Association with Fecal Incontinence. Digestive Diseases and Sciences, 2004, 49, 1040-1045.	1.1	55
111	Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): Study of inflammatory cells and transforming growth factor β1 expression in affected skin. Arthritis and Rheumatism, 2004, 50, 2660-2666.	6.7	196
112	Involvement of skeletal muscle in dialysis-associated systemic fibrosis (nephrogenic fibrosing) Tj ETQq0 0 0 rgBT	/Overlock 1.0	10 Tf 50 622 108
113	Position of single amino acid substitutions in the collagen triple helix determines their effect on structure of collagen fibrils. Journal of Structural Biology, 2004, 148, 326-337.	1.3	41
114	Thermostability Gradient in the Collagen Triple Helix Reveals its Multi-domain Structure. Journal of Molecular Biology, 2004, 338, 989-998.	2.0	37
115	Animal models of systemic sclerosis: insights into systemic sclerosis pathogenesis and potential therapeutic approaches. Current Opinion in Rheumatology, 2004, 16, 746-752.	2.0	28
116	B-Myb acts as a repressor of human COL1A1 collagen gene expression by interacting with Sp1 and CBF factors in scleroderma fibroblasts. Biochemical Journal, 2004, 378, 609-616.	1.7	17
117	Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Annals of Internal Medicine, 2004, 140, 37-50.	2.0	109
118	Systemic sclerosis: current views of its pathogenesis. Autoimmunity Reviews, 2003, 2, 181-191.	2.5	120
119	Skeletal dysplasias and the osteoarthritic phenotype. Best Practice and Research in Clinical Rheumatology, 2003, 17, 1005-1018.	1.4	6
120	Transcriptional activation of $\hat{l}\pm 1$ (III) procollagen gene in Tsk2/+ dermal fibroblasts. Biochemical and Biophysical Research Communications, 2003, 303, 406-412.	1.0	9
121	Regulation of Human COL9A1 Gene Expression. Journal of Biological Chemistry, 2003, 278, 117-123.	1.6	109
122	Detection of Microchimeric Cells in the Peripheral Blood of Nonpregnant Women Is Enhanced by Magnetic Cell Sorting before PCR. Clinical Chemistry, 2003, 49, 309-312.	1.5	7
123	Transcriptional Inhibition of Type I Collagen Gene Expression in Scleroderma Fibroblasts by the Antineoplastic Drug Ecteinascidin 743. Journal of Biological Chemistry, 2003, 278, 40400-40407.	1.6	17
124	Pulmonary and Activation-Regulated Chemokine Stimulates Collagen Production in Lung Fibroblasts. American Journal of Respiratory Cell and Molecular Biology, 2003, 29, 743-749.	1.4	131
125	Modulation of transcriptional activity of collagen genes for the treatment of fibrotic diseases. Expert Opinion on Therapeutic Patents, 2002, 12, 657-664.	2.4	0
126	Oligoclonal T Cell Expansion in the Skin of Patients with Systemic Sclerosis. Journal of Immunology, 2002, 168, 3649-3659.	0.4	185

#	Article	IF	CITATIONS
127	Inhibition of Basal and Transforming Growth Factor-Î ² -induced Stimulation of COL1A1 Transcription by the DNA Intercalators, Mitoxantrone and WP631, in Cultured Human Dermal Fibroblasts. Journal of Biological Chemistry, 2002, 277, 38737-38745.	1.6	24
128	Murine animal models of systemic sclerosis. Current Opinion in Rheumatology, 2002, 14, 671-680.	2.0	30
129	Hepatitis C Virus Infection, Inflammatory Myopathy, and Pulmonary Fibrosis: Are They Related?. Journal of Clinical Rheumatology, 2002, 8, 44-49.	0.5	5
130	Increased Microchimeric CD4+ T Lymphocytes in Peripheral Blood from Women with Systemic Sclerosis. Clinical Immunology, 2002, 103, 303-308.	1.4	65
131	Assessment of the gene expression profile of differentiated and dedifferentiated human fetal chondrocytes by microarray analysis. Arthritis and Rheumatism, 2002, 46, 404-419.	6.7	147
132	Increased life span of human osteoarthritic chondrocytes by exogenous expression of telomerase. Arthritis and Rheumatism, 2002, 46, 683-693.	6.7	79
133	Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis and Rheumatism, 2002, 46, 2410-2420.	6.7	272
134	Collagen II Containing a Cys Substitution for Arg-α1â^'519: Abnormal Interactions of the Mutated Molecules with Collagen IXâ€. Biochemistry, 2001, 40, 14422-14428.	1.2	26
135	Regulation of type-II collagen gene expression during human chondrocyte de-differentiation and recovery of chondrocyte-specific phenotype in culture involves Sry-type high-mobility-group box (SOX) transcription factors. Biochemical Journal, 2001, 360, 461.	1.7	102
136	Regulation of type-II collagen gene expression during human chondrocyte de-differentiation and recovery of chondrocyte-specific phenotype in culture involves Sry-type high-mobility-group box (SOX) transcription factors. Biochemical Journal, 2001, 360, 461-470.	1.7	159
137	Role of protein kinase C-δ in the regulation of collagen gene expression in scleroderma fibroblasts. Journal of Clinical Investigation, 2001, 108, 1395-1403.	3.9	122
138	Detection of cellular microchimerism of male or female origin in systemic sclerosis patients by polymerase chain reaction analysis of HLA–Cw antigens. Arthritis and Rheumatism, 2000, 43, 1062.	6.7	53
139	Inhibition of type I collagen gene expression in normal and systemic sclerosis fibroblasts by a specific inhibitor of geranylgeranyl transferase I. Arthritis and Rheumatism, 2000, 43, 1624-1632.	6.7	28
140	CCAAT binding transcription factor binds and regulates human COL1A1 promoter activity in human dermal fibroblasts: Demonstration of increased binding in systemic sclerosis fibroblasts. Arthritis and Rheumatism, 2000, 43, 2219-2229.	6.7	43
141	Increased numbers of microchimeric cells of fetal origin are associated with dermal fibrosis in mice following injection of vinyl chloride. Arthritis and Rheumatism, 2000, 43, 2598-2605.	6.7	79
142	Alterations in the regulation of expression of the αl(I) collagen gene (COL1A1) in systemic sclerosis (scleroderma). Seminars in Immunopathology, 2000, 21, 397-414.	4.0	24
143	Pemphigus vulgaris induced by D-penicillamine therapy in a patient with systemic sclerosis. Journal of the American Academy of Dermatology, 2000, 42, 297-299.	0.6	32
144	Alterations in the regulation of expression of the ?1(I) collagen gene (COL1A1) in systemic sclerosis (scleroderma). Seminars in Immunopathology, 2000, 21, 397-414.	4.0	7

#	Article	IF	CITATIONS
145	New perspectives on the etiology of systemic sclerosis. Trends in Molecular Medicine, 1999, 5, 74-78.	2.6	34
146	Lack of endothelial cell apoptosis in the dermis of tight skin 1 and tight skin 2 mice. Arthritis and Rheumatism, 1999, 42, 581-584.	6.7	31
147	The mouse tight skin (Tsk) phenotype is not dependent on the presence of mature T and B lymphocytes. Mammalian Genome, 1998, 9, 907-909.	1.0	29
148	Type X collagen biosynthesis and expression in avian tibial dyschondroplasia. Osteoarthritis and Cartilage, 1998, 6, 125-136.	0.6	7
149	Production of cartilage oligomeric matrix protein (COMP) by cultured human dermal and synovial fibroblasts. Osteoarthritis and Cartilage, 1998, 6, 435-440.	0.6	52
150	Effects of interferon-? and tumor necrosis factor ? on the expression of the genes encoding aggrecan, biglycan, and decorin core proteins in cultured human chondrocytes. Arthritis and Rheumatism, 1998, 41, 274-283.	6.7	45
151	Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: A multicenter, placebo-controlled, double-blind study. Arthritis and Rheumatism, 1998, 41, 670-677.	6.7	175
152	Identification of elements in the promoter region of the ?1(I) procollagen gene involved in its up-regulated expression in systemic sclerosis. Arthritis and Rheumatism, 1998, 41, 2048-2058.	6.7	59
153	Transcriptional activation of the ?1(I) procollagen gene and up-regulation of ?1(I) and ?1(III) procollagen messenger RNA in dermal fibroblasts from tight skin 2 mice. Arthritis and Rheumatism, 1998, 41, 2132-2142.	6.7	28
154	Modulation of human $\hat{l}\pm 1$ (I) procollagen gene activity by interaction with Sp1 and Sp3 transcription factors in vitro. Gene, 1998, 215, 101-110.	1.0	73
155	Characterization of human chondrocyte and fibroblast type XII collagen cDNAs. Matrix Biology, 1998, 16, 343-348.	1.5	11
156	Modulation of basal expression of the human α1(I) procollagen gene (COL1A1) by tandem NF-1/Sp1 promoter elements in normal human dermal fibroblasts. Matrix Biology, 1998, 17, 425-434.	1.5	32
157	T Cells Infiltrating the Skin ofTsk2Scleroderma-Like Mice Exhibit T Cell Receptor Bias. Autoimmunity, 1998, 27, 91-98.	1.2	19
158	Differential Regulation of Cyclooxygenases 1 and 2 by Interleukin-1β, Tumor Necrosis Factor-α, and Transforming Growth Factor-β1 in Human Lung Fibroblasts. Experimental Cell Research, 1998, 241, 222-229.	1.2	135
159	Identification of Fetal DNA and Cells in Skin Lesions from Women with Systemic Sclerosis. New England Journal of Medicine, 1998, 338, 1186-1191.	13.9	452
160	The Tight Skin Mouse: Demonstration of Mutant Fibrillin-1 Production and Assembly into Abnormal Microfibrils. Journal of Cell Biology, 1998, 140, 1159-1166.	2.3	109
161	Identification of elements in the promoter region of the $\hat{1}\pm1(I)$ procollagen gene involved in its up-regulated expression in systemic sclerosis. , 1998, 41, 2048.		1
162	Detection and Characterization of Sp1 Binding Activity in Human Chondrocytes and Its Alterations during Chondrocyte Dedifferentiation. Journal of Biological Chemistry, 1997, 272, 26918-26925.	1.6	35

#	Article	IF	CITATIONS
163	Characterization of human type II procollagen and collagen-specific antibodies and their application to the study of human type II collagen processing and ultrastructure. Matrix Biology, 1997, 16, 29-39.	1.5	13
164	Interferon-gamma regulates collagen and fibronectin gene expression by transcriptional and post-transcriptional mechanisms. International Journal of Biochemistry and Cell Biology, 1997, 29, 251-260.	1.2	50
165	Increased activity of the α1(I) procollagen promoter in skin fibroblasts from patients with chronic eosinophilia-myalgia syndrome. International Journal of Biochemistry and Cell Biology, 1997, 29, 135-141.	1.2	7
166	PATHOGENESIS OF SCLERODERMA. Rheumatic Disease Clinics of North America, 1996, 22, 647-674.	0.8	156
167	Transplantation of Systemic Sclerosis (SSc) Skin Grafts into Severe Combined Immunodef icient Mice: Increased Presence of SSc Leukocytes in SSc Skin Grafts and Autoantibody Production following Autologous Leukocyte Transfer. Pathobiology, 1996, 64, 99-114.	1.9	6
168	The transcription of human α1(I) procollagen gene (COL1A1) is suppressed by tumour necrosis factor-α through proximal short promoter elements: evidence for suppression mechanisms mediated by two nuclear-factorbinding sites. Biochemical Journal, 1996, 319, 811-816.	1.7	33
169	Alteration in the conformational stability of collagen caused by the incorporation of the lysine analogue S-2-aminoethylcysteine. BBA - Proteins and Proteomics, 1996, 1294, 37-47.	2.1	9
170	Ultrastructural study of chondrocytes from fibrillated and non-fibrillated human osteoarthritic cartilage. Osteoarthritis and Cartilage, 1996, 4, 111-125.	0.6	78
171	Gastric antral vascular ectasia (watermelon stomach) in patients with systemic sclerosis. Arthritis and Rheumatism, 1996, 39, 341-346.	6.7	98
172	Transcriptional activation of the α1(1) procollagen gene in systemic sclerosis dermal fibroblasts. Role of intronic sequences. Arthritis and Rheumatism, 1996, 39, 1347-1354.	6.7	53
173	Familial Hydroxyapatite Chondrocalcinosis with Spondyloepiphyseal Dysplasia. Journal of Clinical Rheumatology, 1995, 1, 171-178.	0.5	5
174	Mononuciear Cellular Infiltrates in Clinically Involved Skin from Patients with Systemic Sclerosis of Recent Onset Predominantly Consist of Monocytes/Macrophages. Pathobiology, 1995, 63, 48-56.	1.9	152
175	Biosynthesis and characterization of type X collagen in human fetal epiphyseal growth plate cartilage. Osteoarthritis and Cartilage, 1995, 3, 105-116.	0.6	4
176	Elevated levels of eosinophil major basic protein in the sera of patients with systemic sclerosis. Arthritis and Rheumatism, 1995, 38, 939-945.	6.7	25
177	The tight skin 2 mouse. Arthritis and Rheumatism, 1995, 38, 1791-1798.	6.7	97
178	Autoantibodies in Sera from Patients with L-Tryptophan-Associated Eosinophilia-Myalgia Syndrome. Clinical Immunology and Immunopathology, 1995, 76, 115-119.	2.1	4
179	Retroviruses and the Pathogenesis of Systemic Sclerosis. International Reviews of Immunology, 1995, 12, 159-175.	1.5	19
180	Increased α1(I) Procollagen Gene Expression in Tight Skin (TSK) Mice Myocardial Fibroblasts Is Due to a Reduced Interaction of a Negative Regulatory Sequence with AP-1 Transcription Factor. Journal of Biological Chemistry, 1995, 270, 9313-9321.	1.6	35

#	Article	IF	CITATIONS
181	Positive regulation of human α1 (I) collagen promoter activity by transcription factor Sp1. Gene, 1995, 164, 229-234.	1.0	58
182	Animal Models of Scleroderma: Contrasts and Comparisons. International Reviews of Immunology, 1995, 12, 201-216.	1.5	20
183	TGF-β modulates the synthesis of proteoglycans by myocardial fibroblasts in culture. Journal of Molecular and Cellular Cardiology, 1995, 27, 2191-2198.	0.9	55
184	In vitro Cytokine Modulation of Intercellular Adhesion Molecule-1 Expression on Systemic Sclerosis Dermal Fibroblasts. Pathobiology, 1994, 62, 73-81.	1.9	15
185	Identification of a mutation in type X collagen in a family with Schmid metaphyseal chondrodysplasia. Human Molecular Genetics, 1994, 3, 507-509.	1.4	37
186	Familial spondyloepiphyseal dysplasia tarda, brachydactyly, and precocious osteoarthritis associated with an arginine 75 → cysteine mutation in the procollagen type ii gene in a kindred of chiloe islanders Arthritis and Rheumatism, 1994, 37, 1078-1086.	6.7	49
187	Formation of nodular structures resembling mature articular cartilage in long–term primary cultures of human fetal epiphyseal chondrocytes on a hydrogel substrate. Arthritis and Rheumatism, 1994, 37, 1338-1349.	6.7	106
188	Animal models of systemic sclerosis. Clinics in Dermatology, 1994, 12, 425-436.	0.8	24
189	Exclusion of type II and type VI procollagen gene mutations in a five-generation family with multiple epiphyseal dysplasia. American Journal of Medical Genetics Part A, 1993, 45, 345-352.	2.4	14
190	Effects of calcium deficiency on chondrocyte hypertrophy and type X collagen expression in chick embryonic sternum. Developmental Dynamics, 1993, 198, 284-295.	0.8	29
191	Spondyloepiphyseal dysplasia and precocious osteoarthritis in a family with an Arg75?Cys mutation in the procollagen type II gene (COL2A1). Human Genetics, 1993, 92, 499-505.	1.8	94
192	The Tight Skin (Tsk) Mutation in the Mouse, a Model for Human Fibrotic Diseases, Is Tightly Linked to the β2-Microglobulin (B2m) Gene on Chromosome 2. Genomics, 1993, 17, 748-751.	1.3	25
193	Immunological Characterization of (Tight Skin/NZB)F1 Hybrid Mice with Connective Tissue and Autoimmune Features Resembling Human Systemic Sclerosis. Journal of Autoimmunity, 1993, 6, 337-351.	3.0	13
194	Glycosaminoglycans and Chondroitin/Dermatan Sulfate Proteoglycans in the Myocardium of a Non-Human Primate. Matrix Biology, 1993, 13, 363-371.	1.8	5
195	Amplification of cDNAs for Human Cartilage-Specific Types II, IX and XI Collagens from Chondrocytes and Epstein-Barr Virus-Transformed Lymphocytes. Matrix Biology, 1993, 13, 125-133.	1.8	11
196	L-Tryptophan and the Eosinophilia-Myalgia Syndrome: Current Understanding of the Etiology and Pathogenesis Journal of Investigative Dermatology, 1993, 100, 97S-105S.	0.3	23
197	Immunopathogenesis of Systemic Sclerosis: Possible Role of Retroviruses. Autoimmunity, 1993, 16, 225-233.	1.2	14
198	Endoluminal ultrasonography of the distal esophagus in systemic sclerosis. Gastroenterology, 1993, 105, 31-39.	0.6	50

#	Article	IF	CITATIONS
199	L-Tryptophan and the Eosinophilia-Myalgia Syndrome: Current Understanding of the Etiology and Pathogenesis. Journal of Investigative Dermatology, 1993, 100, S97-S105.	0.3	37
200	In situ Expression of Cytokines and Cellular Adhesion Molecules in the Skin of Patients with Systemic Sclerosis. Pathobiology, 1993, 61, 239-246.	1.9	166
201	HEREDITY, GENES AND OSTEOARTHRITIS. Rheumatic Disease Clinics of North America, 1993, 19, 523-543.	0.8	18
202	Polymerase chain reaction — amplification of the coding sequence of the type X collagen gene from genomic DNA and identification of a polymorphism that changes GLY to ARG at position 545 by single-strand conformation polymorphism analysis. Biochemical and Biophysical Research Communications, 1992, 187, 420-424.	1.0	1
203	EOSINOPHILIA-MYALGIA SYNDROME. International Journal of Dermatology, 1992, 31, 223-228.	0.5	10
204	Autoantibodies to Nuclear Lamin C in the Eosinophilia—Myalgia Syndrome Associated with L-Tryptophan Ingestion. Arthritis and Rheumatism, 1992, 35, 106-109.	6.7	19
205	Elevated expression of β1 and β2 integrins, intercellular adhesion molecule 1, and endothelial leukocyte adhesion molecule 1 in the skin of patients with systemic sclerosis of recent onset. Arthritis and Rheumatism, 1992, 35, 290-298.	6.7	95
206	Treatment of systemic sclerosis with recombinant interferon-γ. A phase I/II clinical trial. Arthritis and Rheumatism, 1992, 35, 1134-1142.	6.7	78
207	Structure of cDNAs Encoding the Triple-Helical Domain of Murine α2 (VI) Collagen Chain and Comparison to Human and Chick Homologues. Use of Polymerase Chain Reaction and Partially Degenerate Oligonucleotides for Generation of Novel cDNA Clones. Matrix Biology, 1991, 11, 1-9.	1.8	46
208	The eosinophilia-myalgia syndrome and eosinophilic fasciitis. Current Opinion in Rheumatology, 1991, 3, 986-994.	2.0	10
209	Elevated Expression of the Genes for Transforming Growth Factor-β1 and Type VI Collagen in Diffuse Fasciitis Associated with the Eosinophilia-Myalgia Syndrome. Journal of Investigative Dermatology, 1991, 96, 20-25.	0.3	45
210	Comparison of morphological and biochemical characteristics of cultured chondrocytes isolated from proliferative and hypertrophic zones of bovine growth plate cartilage. Differentiation, 1991, 46, 199-207.	1.0	19
211	Evidence for autoimmunity in the tight skin mouse model of systemic sclerosis. Arthritis and Rheumatism, 1991, 34, 599-605.	6.7	44
212	The eosinophilia-myalgia syndrome and eosinophilic fasciitis. Current Opinion in Rheumatology, 1990, 2, 960-966.	2.0	7
213	Evaluation of Transforming Growth Factor β and Type I Procollagen Gene Expression in Fibrotic Skin Disease by In Situ Hybridization. Journal of Investigative Dermatology, 1990, 94, 365-371.	0.3	146
214	Clinical spectrum of the systemic manifestations of the eosinophilia-myalgia syndrome. Seminars in Arthritis and Rheumatism, 1990, 19, 313-328.	1.6	49
215	Increased expression of type VI collagen genes in systemic sclerosis. Arthritis and Rheumatism, 1990, 33, 1829-1835.	6.7	96
216	Transforming Growth Factor-? Stimulates the Expression of Prostaglandin Synthase in Normal Human Fibroblasts. Annals of the New York Academy of Sciences, 1990, 593, 306-308.	1.8	1

#	Article	IF	CITATIONS
217	Interferon-? Modulates the Effect of Transforming Growth Factor-? on Extracellular Matrix Gene Expression by Fibroblasts. Annals of the New York Academy of Sciences, 1990, 593, 321-322.	1.8	1
218	Genetic Linkage of a Polymorphism in the Type II Procollagen Gene (COL2A1) to Primary Osteoarthritis Associated with Mild Chondrodysplasia. New England Journal of Medicine, 1990, 322, 526-530.	13.9	178
219	Animal Models of Fibrosis. Rheumatic Disease Clinics of North America, 1990, 16, 153-167.	0.8	18
220	Other fibrosing syndromes. Current Opinion in Rheumatology, 1989, 1, 516-522.	2.0	0
221	The Tight Skin (TSK) Mouse. Monographs on Pathology of Laboratory Animals, 1989, , 209-218.	0.0	1
222	Progressive systemic sclerosis: Mode of presentation, rapidly progressive disease course, and mortality based on an analysis of 91 patients. Seminars in Arthritis and Rheumatism, 1988, 18, 1-13.	1.6	76
223	Detection of nuclear lamin B epitopes in oocyte nuclei from mice, sea urchins, and clams using a human autoimmune serum. Developmental Biology, 1987, 121, 368-375.	0.9	33
224	Barrett's metaplasia and adenocarcinoma of the esophagus in scleroderma. American Journal of Medicine, 1987, 82, 46-52.	0.6	123
225	PGE2 causes a coordinate decrease in the steady state levels of fibronectin and types I and III procollagen mRNAs in normal human dermal fibroblasts. Biochemical and Biophysical Research Communications, 1987, 147, 1282-1288.	1.0	95
226	Expression of Type X collagen mRNA levels in embryonic chick sternum during development. Biochemical and Biophysical Research Communications, 1986, 137, 1125-1132.	1.0	11
227	Stimulation of normal human fibroblast collagen production and processing by transforming growth factor-β. Biochemical and Biophysical Research Communications, 1986, 138, 974-980.	1.0	143
228	Penicillamine-Induced Rapidly Progressive Glomerulonephritis in Patients With Progressive Systemic Sclerosis: Successful Treatment of Two Patients and a Review of the Literature. American Journal of Kidney Diseases, 1986, 8, 159-163.	2.1	47
229	Development of Rheumatoid Factors and Anti-F(ab′) ₂ Antibodies in Guinea Pigs Immunized with Type II Bovine Collagen. International Archives of Allergy and Immunology, 1986, 80, 214-220.	0.9	9
230	Inhibition of excessive scleroderma fibroblast collagen production by recombinant Î ³ -interferon: Association with a coordinate decrease in types I and III procollagen messenger RNA levels. Arthritis and Rheumatism, 1986, 29, 851-856.	6.7	106
231	Development of severe limited scleroderma in complicated Raynaud's phenomenon after limb immobilization: Report of two cases and study of collagen biosynthesis. Arthritis and Rheumatism, 1986, 29, 1160-1165.	6.7	9
232	Regulation of fibroblast proliferation and collagen synthesis by cytokines. Trends in Immunology, 1986, 7, 303-307.	7.5	144
233	Selective inhibition of excessive scleroderma fibroblast collagen production by lymphokines from normal human mononuclear cells. Arthritis and Rheumatism, 1985, 28, 502-510.	6.7	21
234	Transcriptional Control of Human Diploid Fibroblast Collagen Synthesis by ?-Interferon. Annals of the New York Academy of Sciences, 1985, 460, 453-455.	1.8	0

#	Article	IF	CITATIONS
235	Scleroderma-like alterations in collagen metabolism occurring in the TSK (tight skin) mouse. Arthritis and Rheumatism, 1984, 27, 180-185.	6.7	74
236	Increased biosynthesis of glycosaminoglycans by scleroderma fibroblasts in culture. Arthritis and Rheumatism, 1984, 27, 1040-1045.	6.7	24
237	Sequential changes in the mechanical properties of viable articular cartilage storedin vitro. Journal of Orthopaedic Research, 1984, 2, 55-60.	1.2	15
238	Transcriptional control of human diploid fibroblast collagen synthesis by Î ³ -interferon. Biochemical and Biophysical Research Communications, 1984, 123, 365-372.	1.0	136
239	The Regulation of Lung Fibroblast Proliferation by Alveolar Macrophages in Experimental Silicosis1–3. The American Review of Respiratory Disease, 1984, 129, 767-771.	2.9	71
240	Biosynthesis of a Low Molecular Weight Collagen by Rabbit Growth Plate Cartilage Organ Cultures. Collagen and Related Research, 1983, 3, 271-278.	2.2	44
241	Characterization of a lymphokine produced by human T cells which inhibits collagen synthesis. Cellular Immunology, 1983, 81, 192-198.	1.4	16
242	Cellular immune dysfunction and the pathogenesis of scleroderma. Seminars in Arthritis and Rheumatism, 1983, 13, 104-113.	1.6	38
243	Biochemical Characterization of Collagens and of a Non-Collagenous Protein Synthesized by Guinea Pig Lung Fibroblasts in Culture. Connective Tissue Research, 1983, 12, 17-31.	1.1	14
244	Immune modulation of connective tissue functions: Studies on the production of collagen synthesis inhibitory factor by populations of human peripheral blood mononuclear cells. Cellular Immunology, 1982, 74, 126-139.	1.4	24
245	Inhibition of proteoglycan degradation in rabbit articular cartilage organ cultures by superoxide dismutase and proteolytic enzyme inhibitors. Seminars in Arthritis and Rheumatism, 1981, 11, 98-99.	1.6	2
246	The gastrointestinal manifestations of scleroderma: Pathogenesis and management. Gastroenterology, 1980, 79, 155-166.	0.6	219
247	Synovitis in secondary syphilis. Arthritis and Rheumatism, 1979, 22, 170-176.	6.7	41
248	Articular cartilage preservation and storage. Arthritis and Rheumatism, 1979, 22, 1093-1101.	6.7	58
249	Effect of various aminoacid analogues on chick tendon procollagen synthesis and secretion: Selective inhibition by S-2-aminoethyl cysteine. Biochemical and Biophysical Research Communications, 1979, 91, 1330-1336.	1.0	7
250	Isolation and partial characterization of proteoglycans from sheep lung parenchyma. Biochimica Et Biophysica Acta - General Subjects, 1979, 588, 129-141.	1.1	9
251	Identification of two new collagen α-chains in extracts of lathyritic chick embryo tendons. Biochemical and Biophysical Research Communications, 1978, 81, 1298-1306.	1.0	40
252	Increased sensitivity of scleroderma fibroblasts in culture to stimulation of protein and collagen synthesis by serum. Biochemical and Biophysical Research Communications, 1977, 76, 1214-1222.	1.0	37

#	Article	IF	CITATIONS
253	Identification of collagen $\hat{I}\pm1(I)$ trimer in embryonic chick tendons and calvaria. Biochemical and Biophysical Research Communications, 1977, 78, 1354-1361.	1.0	123
254	Effects of trypsin on the platelet-aggregating activity of mouse tumor cells. Thrombosis Research, 1977, 10, 33-45.	0.8	20
255	Collagen synthesis by scleroderma fibroblasts in culture. Arthritis and Rheumatism, 1977, 20, 902-903.	6.7	32
256	Simultaneous aggregation and release from platelets monitored continuously in plasma. Thrombosis Research, 1976, 9, 553-563.	0.8	9
257	Acute gouty arthritis without urate crystals identified on initial examination of synovial fluid. Arthritis and Rheumatism, 1975, 18, 603-612.	6.7	43
258	Secretion of unhydroxylated chick tendon procollagen. Biochemical and Biophysical Research Communications, 1975, 67, 735-740.	1.0	15
259	Decreased thermal stability of collagens containing analogs of proline or lysine. Archives of Biochemistry and Biophysics, 1974, 163, 459-465.	1.4	50
260	Effects of Temperature on Conformation, Hydroxylation, and Secretion of Chick Tendon Procollagen. Journal of Biological Chemistry, 1974, 249, 4480-4486.	1.6	49
261	Hydroxyproline stabilizes the triple helix of chick tendon collagen. Biochemical and Biophysical Research Communications, 1973, 52, 106-114.	1.0	201
262	Hydroxyproline content determines the denaturation temperature of chick tendon collagen. Archives of Biochemistry and Biophysics, 1973, 158, 478-484.	1.4	225
263	Intracellular Collagen and Protocollagen from Embryonic Tendon Cells. Journal of Biological Chemistry, 1973, 248, 720-729.	1.6	101
264	Characterization of the precursor forms of the α1 and α2 chains of collagen from matrix-free tendon cells. Biochimica Et Biophysica Acta (BBA) - Protein Structure, 1972, 278, 198-205.	1.7	25
265	Further evidence for a transport form of collagen. Its extrusion and extracellular conversion to tropocollagen in embryonic tendon. FEBS Letters, 1971, 17, 245-248.	1.3	129